impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

One year in review

 

Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024

1, 2, 3

 

  1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. dr.g.demattia@gmail.com
  2. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  3. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

CER17979
2024 Vol.42, N°7
PI 1311, PF 1316
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 39026507 [PubMed]

Received: 01/07/2024
Accepted : 08/07/2024
In Press: 18/07/2024
Published: 18/07/2024

Abstract

Osteoporosis is a skeletal disease characterised by reduced bone mass and deterioration of bone microarchitecture, underlying a higher risk of fragility fractures. Several options are available for its treatment, including both anti-resorptive and anabolic agents. The present review discusses and summarises the most recent literature on anabolic treatment, with a focus on abaloparatide, and on the assessment of fragility fracture risk, with a focus on trabecular bone score. Finally, we provide a discussion on the effects of different antiosteoporotic medications in terms of fragility fracture risk reduction.

DOI: https://doi.org/10.55563/clinexprheumatol/7f52vl

Rheumatology Article